The international model and diabetes advocate on career, self-confidence and being the change she wants to see.

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...